A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Rituximab (Primary) ; Mycophenolate mofetil
  • Indications Pemphigus vulgaris
  • Focus Therapeutic Use
  • Acronyms PEMPHIX
  • Sponsors Roche
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 May 2019 to 7 Sep 2019.
    • 16 Mar 2017 Planned primary completion date changed from 1 May 2019 to 30 Sep 2018.
    • 01 Feb 2016 Planned End Date changed from 1 Feb 2019 to 1 May 2019 reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top